Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 2/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9005323 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2SLC22A6GABRR1LMNAMAPT | |
| SCHEMBL6453593 | 0.83 | SLC22A6 (0.75) | SMN1; SMN2SLC22A6GABRR1LMNAMAPT | |
| SCHEMBL20134681 | 0.81 | SLC22A6 (0.63) | SMN1; SMN2SLC22A6GABRR1LMNAMAPT | |
| SCHEMBL25427974 | 0.78 | SLC22A6 (0.67) | SMN1; SMN2SLC22A6GABRR1LMNAMAPT | |
| SCHEMBL27928314 | 0.78 | TET2 (0.48) | SMN1; SMN2SLC22A6TET2KDM4AKDM4C | |
| Malic Acid SCHEMBL14125844 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2SLC22A6GABRR1LMNATET2 | |
| Malic Acid SCHEMBL856 | 0.77 | — | — | |
| Malic Acid SCHEMBL256122 | 0.77 | — | — | |
| Malic Acid SCHEMBL98496 | 0.77 | — | — | |
| Malic Acid SCHEMBL89131 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2SLC22A6GABRR1LMNATET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109659604-B | Solid electrolyte composite material and preparation method and application thereof | 北京大学深圳研究生院 | 2020-09-01 | — | — | CN | claimed |
| CN-109659604-A | A kind of solid electrolyte composite material and preparation method and application | 北京大学深圳研究生院 | 2019-04-19 | — | — | CN | claimed |
| CN-105745327-A | High-yield route for producing compounds from renewable resources | 兹莫克姆有限公司 | 2016-07-06 | — | — | CN | claimed |
| EP-1439162-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORP (JP) | 2008-03-26 | — | — | EP | claimed |
| US-6998495-B2 | Method for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2006-02-14 | — | — | US | claimed |
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1439162-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORPORATION (JP) | 2004-07-21 | — | — | EP | claimed |
| EP-0464817-B1 | 2,4-Dihydroxyadipic acid derivative | KANEGAFUCHI CHEMICAL IND (JP) | 1996-10-09 | — | — | EP | claimed |
| US-5214197-A | 2,4-DIHYDROXYADIPIC ACID DERIVATIVE | KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-05-25 | — | — | US | claimed |
| EP-0464817-A1 | 2,4-Dihydroxyadipic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1992-01-08 | — | — | EP | claimed |
| JP-4069355-A | — | — | None | — | — | JP | disclosed |
| US-12104160-B2 | Production of 4,6-dihydroxy-2-oxo-hexanoic acid | ZYMOCHEM, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | TOPIKOS PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220389433-A1 | HIGH YIELD ROUTE FOR THE PRODUCTION OF COMPOUNDS FROM RENEWABLE SOURCES | ZYMOCHEM, INC. | 2022-12-08 | — | — | US | disclosed |
| US-5214197-A | 2,4-DIHYDROXYADIPIC ACID DERIVATIVE | KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| JP-H0469355-A | 2,4-DIHYDROXYADIPIC ACID DERIVATIVE | KANEGAFUCHI CHEM IND CO LTD | 1992-03-04 | — | — | JP | disclosed |
| EP-0464817-A1 | 2,4-Dihydroxyadipic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464817-A1 | 2,4-Dihydroxyadipic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464817-A1 | 2,4-Dihydroxyadipic acid derivative | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | HAO2, GRHPR, HDHD5 | SMN1; SMN2 4843/4885SLC22A6 4289/4885GABRR1 196/4885 |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | SMN1; SMN2 3283/4885SLC22A6 1842/4885GABRR1 3637/4885 |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | SMN1; SMN2 3283/4885SLC22A6 1842/4885GABRR1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.